ESG206 / Escugen Biotechnology - LARVOL DELTA

Interim report of a phase 1/2 study of ESG206 in patients with refractory or relapsed primary immune thrombocytopenia (ASH 2025) - P1/2 | "Patients were previouslytreated with a median (range) of 4 (1–7) prior ITP therapies, including CS (100%), TPO-RAs (40%),rituximab (20%), and other immunosuppressants. These represent the first data on ESG206 in patients with primary ITP. Preliminary findingssuggest that partial administration of the ESG206 treatment schedule already demonstrated rapid andencouraging efficacy with a favorable tolerability profile in heavily pretreated patients withrelapsed/refractory ITP. These early interim results support further clinical exploration of ESG206 in thispopulation."

Clinical • P1/2 data • Hematological Malignancies • Immune Thrombocytopenic Purpura • Thrombocytopenia • Thrombocytopenic Purpura • CD20

A First-in-Human Phase I Study of ESG206 in Subjects With B-cell Lymphoid Malignancies (clinicaltrials.gov) - P1 | N=0 | Withdrawn | Sponsor: Shanghai Escugen Biotechnology Co., Ltd | N=12 ➔ 0 | Not yet recruiting ➔ Withdrawn

Enrollment change • First-in-human • Trial withdrawal • Hematological Malignancies • Oncology

A Phase 1 Study of ESG206 in Adult Subjects With B-cell Lymphoid Malignancies (clinicaltrials.gov) - P1 | N=13 | Completed | Sponsor: Shanghai Escugen Biotechnology Co., Ltd | N=10 ➔ 13 | Trial completion date: Dec 2025 ➔ Jan 2025 | Trial primary completion date: Aug 2025 ➔ Jan 2025 | Recruiting ➔ Completed

Enrollment change • Trial completion • Trial completion date • Trial primary completion date • Hematological Malignancies • Oncology

A Phase 1/2 Study of ESG206 in Patients With Primary Immune Thrombocytopenia (clinicaltrials.gov) - P1/2 | N=84 | Recruiting | Sponsor: Shanghai Escugen Biotechnology Co., Ltd | Not yet recruiting ➔ Recruiting

Enrollment open • Hematological Disorders • Immune Thrombocytopenic Purpura • Thrombocytopenia • Thrombocytopenic Purpura

A Phase 1 Study of ESG206 in Adult Subjects With B-cell Lymphoid Malignancies (clinicaltrials.gov) - P1 | N=10 | Recruiting | Sponsor: Shanghai Escugen Biotechnology Co., Ltd | Trial completion date: Mar 2025 ➔ Dec 2025 | Trial primary completion date: Nov 2024 ➔ Aug 2025

Trial completion date • Trial primary completion date • Hematological Malignancies • Oncology

A Phase 1/2 Study of ESG206 in Patients with Primary Immune Thrombocytopenia (clinicaltrials.gov) - P1/2 | N=84 | Not yet recruiting | Sponsor: Shanghai Escugen Biotechnology Co., Ltd

New P1/2 trial • Hematological Disorders • Immune Thrombocytopenic Purpura • Thrombocytopenia • Thrombocytopenic Purpura

A First-in-Human Phase I Study of ESG206 in Subjects With B-cell Lymphoid Malignancies (clinicaltrials.gov) - P1 | N=12 | Not yet recruiting | Sponsor: Shanghai Escugen Biotechnology Co., Ltd | Trial completion date: May 2025 ➔ Dec 2026 | Trial primary completion date: Jan 2025 ➔ Aug 2026

Trial completion date • Trial primary completion date • Hematological Malignancies • Oncology

Preliminary results of a first-in-human study on ESG206, a novel anti-BAFF-R monoclonal antibody, in relapsed or refractory B-cell malignancies. (ASCO 2024) - P1 | "Preclinical investigations have successfully validated the antitumor effects of ESG206 across a spectrum of malignant B cell disease models, including lymphoma xenografts which were resistant to Rituximab, and Ibrutinib. Preliminary data indicates ESG206 is well-tolerated with promising efficacy signals in R/R B-cell malignancies. These encouraging results warrant continued clinical evaluation as the Phase I study progresses. Clinical trial information: NCT05263739."

P1 data • Anemia • Diffuse Large B Cell Lymphoma • Dyslipidemia • Follicular Lymphoma • Hematological Disorders • Hematological Malignancies • Infectious Disease • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Respiratory Diseases • Solid Tumor

A Phase 1 Study of ESG206 in Adult Subjects With B-cell Lymphoid Malignancies (clinicaltrials.gov) - P1 | N=10 | Recruiting | Sponsor: Shanghai Escugen Biotechnology Co., Ltd | Not yet recruiting ➔ Recruiting

Enrollment open • Hematological Malignancies • Oncology

A Phase 1 Study of ESG206 in Adult Subjects With B-cell Lymphoid Malignancies (clinicaltrials.gov) - P1 | N=10 | Not yet recruiting | Sponsor: Shanghai Escugen Biotechnology Co., Ltd

New P1 trial • Hematological Malignancies • Oncology

A First-in-Human Phase I Study of ESG206 in Subjects With B-cell Lymphoid Malignancies (clinicaltrials.gov) - P1 | N=12 | Not yet recruiting | Sponsor: Shanghai Escugen Biotechnology Co., Ltd | Trial completion date: May 2024 ➔ May 2025 | Trial primary completion date: Jan 2024 ➔ Jan 2025

Trial completion date • Trial primary completion date • Hematological Malignancies • Oncology

A First-in-Human Phase I Study of ESG206 in Subjects With B-cell Lymphoid Malignancies (clinicaltrials.gov) - P1 | N=12 | Not yet recruiting | Sponsor: Shanghai Escugen Biotechnology Co., Ltd | Initiation date: May 2022 ➔ Sep 2022

Trial initiation date • Hematological Malignancies • Oncology